Eurasia Huizhi (Beijing) Medical Research Co., Ltd
Eurasia Huizhi (Beijing) Medical Research Co., Ltd

Eurasia Huizhi (Beijing) Medical Research Co., Ltd

Eurasia Huizhi (Beijing) Medical Research Co., Ltd. is a Contract Research Organization (CRO) that provides specialized clinical trial services to pharmaceutical companies. The company adheres to the principles of integrity, win-win cooperation, diligence, and professionalism, offering high-quality solutions to its partners for new drug development. Through superior approaches, we help clients enhance R&D efficiency, reduce R&D risks, save R&D costs, and accelerate the commercialization of their products. With patients at the core, guided by clinical value, and aiming to meet unmet clinical needs, we continuously create new value for the healthcare industry.

We have over 17 years of experience in clinical trial research, consistently pursuing professional industry quality standards. With valuable expertise gained from more than 500 projects, we have played a pivotal role in every trial across over 20 research areas, including oncology/hematologic malignancies, endocrinology, neuropsychiatry, cardiovascular, digestive, respiratory, rheumatologic and immunologic disorders, and otolaryngology.

17 + years

Clinical Trial Research Process

15 + years

Operations Management Expert Team

200 +name

Experienced clinical operations team

500 +

Project Undertaking

200 +

Clinical Trial Research Experience

60 + one

Deep strategic cooperation center, with highly compatible and efficient Phase I clinical resources.

100 +name

Early Clinical Research Expert Team

10 + item

Invention patent

6 + item

Software Copyright

6 Item

National Key Special Project

Business content

Registration Affairs

Registration Affairs

View details

Early clinical development

Early clinical development

View details

Phase II-IV Clinical Trials

Phase II-IV Clinical Trials

View details

Post-Marketing Reevaluation Study

Post-Marketing Reevaluation Study

View details

Medical Affairs

Medical Affairs

View details

Quality Assurance Services

Quality Assurance Services

View details

Generic Drug Clinical Studies

Generic Drug Clinical Studies

View details

Personnel Outsourcing (FSP) Services

Personnel Outsourcing (FSP) Services

View details

Solution

Medical - Registration Affairs

Customized services, a trusted partner Well-versed in domestic and international laws, regulations, and technical guidelines: Accurately grasp the current review philosophies and cutting-edge information from NMPA, FDA, and EMA, maintaining forward-looking insights to provide clients with feasible strategies and solutions. Embedding registration-outcome-oriented and closely integrated strategies into clinical solutions: We have a deep understanding of local culture and have maintained excellent, open communication channels with regulatory authorities—from CFDA through NMPA—accumulating extensive experience and resources in both technical and regulatory matters. Gained drug registration experience from over 200 projects: Our registration strategies have been recognized by NMPA; several emerging biologics—including cell therapies and oncolytic viruses—have received accelerated reviews, facilitating conditional marketing approval for rare-disease projects, and cell therapy projects have steadily increased year after year. Efficient clinical study design—effectively controlling drug development costs: Thanks to our specialized medical team and experienced expert panel’s advanced strategy formulation and scientific design, we’ve participated in the evaluation of nearly 1,000 drug candidates, with innovative drug services accounting for over 60% of our work in the past five years.
Medical - Registration Affairs

Clinical Operations

The core management team excels in strategic and tactical operational coordination and demonstrates strong capabilities in identifying and managing policy risks!
Clinical Operations

Clinical Resources

Over 300 nationally accredited GCP clinical centers More than 1,200 experts at or above the level of associate chief physician in long-term collaboration Clinical operations teams covering over 30 regions nationwide The above research center resources are recommended and matched to PIs based on the specific project.
Clinical Resources

Project Experience

Project Experience

Value-added services

Providing value-added services for strategic partners Professional Project Evaluation Multi-dimensional assessments including drug-likeness analysis, clinical operational risk analysis, and clinical value analysis Professional Registration Support Registration feasibility assessment, issue resolution, and regulatory affairs support
Value-added services

Reflect deeply, pool wisdom, and pursue excellence.

Hematologic Malignancies Two-thirds of our project managers and directors have experience in hematologic oncology. Our research network covers the entire country; a single pivotal clinical study alone manages 80 hematology clinical sites, with collaboration involving key opinion leaders and department directors. Over the past five years, our team has conducted more than 20 clinical trials for hematologic malignancies, enrolling over 3,000 patients across the following indications: Leukemia Lymphoma Multiple myeloma Chronic Myelomonocytic Leukemia Non-Hodgkin Lymphoma Myeloproliferative Neoplasms Cell Therapy (Stem Cells and Immune Cells) Over the past five years, our team has conducted more than 10 cell therapy studies and successfully helped clients overcome numerous technical challenges, enabling them to obtain clinical approvals. We possess specialized expertise, technical skills, and extensive experience. We have a deep understanding of the regulatory policies specific to this field. We have extensive experience in registering clinical trials and conducting Investigational New Drug (IIT) studies. Immune cells are primarily used in cancer treatment, while stem cells are more focused on tissue repair and the treatment of chronic diseases. Currently, cell therapy has already seen widespread application in hematologic disorders and demonstrates favorable outcomes—for example, CAR-T cell therapy has achieved an 82% response rate in patients with acute lymphoblastic leukemia. Cell therapy is also playing an increasingly important role in the exploration and treatment of solid tumors.
Reflect deeply, pool wisdom, and pursue excellence.

News Updates

Company News Article published Industry regulations
MA Achievement Release | Agomelatine Tablets Have Obtained Registration Approval!

MA Achievement Release | Agomelatine Tablets Have Obtained Registration Approval!

Congratulations to Chongqing Huasen Pharmaceutical Co., Ltd. on obtaining the registration certificate for the agomelatine tablet project.

MA Results Release | Huasen Pharmaceutical—Terazosin Hydrochloride Capsules Approved!

MA Results Release | Huasen Pharmaceutical—Terazosin Hydrochloride Capsules Approved!

Congratulations to Chongqing Huasen Pharmaceutical Co., Ltd. on receiving the “Drug Approval Notice” for its Terazosin Hydrochloride Capsules (2mg) project!

A New Beginning, a New Journey—Warmly Celebrating the Official Establishment of the Eurasia Huizhi Shanghai Office

A New Beginning, a New Journey—Warmly Celebrating the Official Establishment of the Eurasia Huizhi Shanghai Office

Due to the company's growth, Eurasia Huizhi (Beijing) Medical Research Co., Ltd. officially established a Shanghai office on February 19, 2021.

A seminar on a clinical study protocol for non-small cell lung cancer was successfully held.

A seminar on a clinical study protocol for non-small cell lung cancer was successfully held.

During the period of regular COVID-19 prevention and control, our company successfully held an online proposal discussion meeting!

See more +